UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/593,870	07/31/2007	Kun'ichi Miyazawa	2006_1609A	4399
513 7590 03/24/2010 WENDEROTH, LIND & PONACK, L.L.P. 1030 15th Street, N.W., Suite 400 East Washington, DC 20005-1503			EXAMINER	
			MCCRACKEN, DANIEL	
			ART UNIT	PAPER NUMBER
			1793	
			NOTIFICATION DATE	DELIVERY MODE
			03/24/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ddalecki@wenderoth.com eoa@wenderoth.com

	Application No.	Applicant(s)			
	10/593,870	MIYAZAWA ET AL.			
Office Action Summary	Examiner	Art Unit			
	DANIEL C. MCCRACKEN	1793			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	Lely filed the mailing date of this communication. (35 U.S.C. § 133).			
Status					
1)⊠ Responsive to communication(s) filed on 22 Se	entember 2006				
3) Since this application is in condition for allowar		secution as to the merits is			
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) ☐ Claim(s) 10-21 is/are pending in the application 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 10-21 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	vn from consideration.				
Application Papers					
9) ☐ The specification is objected to by the Examine 10) ☑ The drawing(s) filed on 22 September 2006 is/a Applicant may not request that any objection to the orection Replacement drawing sheet(s) including the correction The oath or declaration is objected to by the Examine 11.	re: a) accepted or b) object drawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	ected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ite			

DETAILED ACTION

Citation to the Specification will be in the following format: (S. #: \P/L) where # denotes the page number and ¶/L denotes the paragraph number or line number. Citation to patent literature will be in the form (Inventor # : LL) where # is the column number and LL is the line number. Citation to the pre-grant publication literature will be in the following format (Inventor #: ¶) where # denotes the page number and ¶ denotes the paragraph number.

Status of Application

Applicants preliminary amendment dated 9/22/2006 has been received and will be entered. Claims 10-21 are pending and new. Claims 1-9 are acknowledged as cancelled.

Priority

Receipt is acknowledged of papers submitted under 35 U.S.C. 119(a)-(d), which papers have been placed of record in the file.

Information Disclosure Statement

The information disclosure statement (IDS) submitted on 12/20/2006 was prior to the mailing date of the first action on the merits. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

The listing of references in the specification - *see* (S. 2: 3) - is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.

Drawings

New corrected drawings in compliance with 37 CFR 1.121(d) are required in this application because the copies submitted appear to be faxes of photocopies, and unsuitable for reproduction in the event a patent ever issues. Consult the copy in PAIR and note the unintelligibility of the product and scale in *e.g.* "Fig. 3." Applicant is advised to employ the services of a competent patent draftsperson outside the Office, as the U.S. Patent and Trademark Office no longer prepares new drawings. The corrected drawings are required in reply to the Office action to avoid abandonment of the application. The requirement for corrected drawings will not be held in abeyance.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Application/Control Number: 10/593,870

Art Unit: 1793

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

Page 4

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

I. Claims 10-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over US 2002/0192143 to Miyazawa, et al. in view of Fagan, et al., *Metal Complexes of Buckminsterfullerene* (C_{60}), Acc. Chem. Res. 1992; 25: 134-142 (hereinafter "Fagan at __").

With respect to Claim 17-18, Miyazawa teaches a method for making "needle crystals" via a liquid-liquid interface method. See generally (Miyazawa 6: [0151] et seq.) Note with respect to Claims 20-21 that both toluene (Miyazawa 7: [0163]) and isopropyl alcohol (Miyazawa 7: [0174]) are taught. Claims 17-18 and Claim 19 differ from Miyazawa in that they they require a C₆₀ platinum derivative, not taught by Miyazawa. This however does not impart patentability. Note the teachings of Miyazawa suggesting that different fullerenes can be added to the needle/wire (Miyazawa 5: [0111]) and that dopants can be added to improve properties of the needle (Miyazawa 6: [0141] et seq.). C₆₀ platinum derivatives, including the specific species of Claim 19 are known in the art. See e.g. (Fagan at 138, col. 1) (note that $C_6H_5 = Ph$). Substitution of the derivatives of Fagan for the fullerenes taught by Miyazawa is an obvious expedient, the articulated rationale being that it would appear to be application of a known method (Miyazawa's liquid-liquid interface precipitation method) product/composition (the fullerene derivative of Fagan), ready for improvement (note the suggestion of improving properties by adding dopants/fullernes) to yield predictable results. See

MPEP 2143. Furthermore, note the advantages in Fagan related to controlling the reactivity of C_{60} by adding the Pt moieties. (Fagan at 141, col. 2).

<u>Claims 10-16</u> are claims directed to the resulting product of the reactions addressed above in connection with Claims 17-21. Note that the morphologies in <u>Claims 12 and 14</u> are taught. (Miyazawa 5: [0132] *et seq.*) ("hollow portions") *and e.g.* (Miyazawa "Fig 28") (showing a closed form). As to <u>Claims 13 and 15</u>, these are product-by-process claims. The process steps are not given patentable weight except to the extent they suggest structural or compositional features. *See* MPEP 2113. Here, the features suggested are dry needles, reasonably suggested by Miyazawas various micrographs. Note also that Miyazawa explicitly provides for heating. (Miyazawa 9: [0221]). As to <u>Claims 10, 11, and 16</u>, see the Fagan reference and discussion *supra*.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIEL C. MCCRACKEN whose telephone number is (571)272-6537. The examiner can normally be reached on Monday through Friday, 9 AM - 6 PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Stanley S. Silverman can be reached on (571) 272-1358. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/593,870

Art Unit: 1793

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Page 6

/Daniel C. McCracken/ Daniel C. McCracken Examiner, Art Unit 1793 DCM